Temsirolimus
Colon Neoplasms
Vejle HospitalSmall moleculePhase 2Dormant
B
63/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 48/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Colon Neoplasms cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
azd6244 AstraZeneca | Phase 2 | BB |
DACARBAZINE AstraZeneca | Phase 1 | CC |
gi-6301 ImmunityBio, Inc. | Phase 1/2 | C |
Same molecule, other indications
Temsirolimus is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →